Lancôme Unveils Absolue Longevity MD Line Powered by Mitopure
Longevity science has been making its way through the supplement aisle for years. Now it has a luxury skincare address. On March 27, 2026, Lancôme used the stage of the American Academy of Dermatology (AAD) annual meeting in Denver to debut Absolue Longevity MD, a three-product line built around Mitopure, a proprietary form of Urolithin A developed by Swiss biotech firm Timeline.
What Urolithin A Actually Does in Skin
Think of skin cells the way you’d think of any engine: they run on fuel, and that fuel comes from mitochondria. As we age, damaged mitochondria accumulate inside cells, dragging down energy output and accelerating visible aging. Urolithin A’s mechanism is to trigger mitophagy, the cellular process that clears out those dysfunctional mitochondria so healthy ones can take over. It’s cellular self-cleaning, not surface-level repair.
Mitopure is Timeline’s patented, purified form of Urolithin A, backed by clinical data gathered primarily in the ingestible supplement market. Lancôme’s move brings this science into topical skincare, a meaningful extension of a molecule that has been proven orally but is newer in applied skin research.
Three Products, Three Phases of Aging
The line launches as three distinct SKUs: Anticipate, Intercept, and Reset. The naming itself signals the brand’s positioning. Anticipate addresses prevention before visible aging sets in; Intercept targets early-stage changes; Reset focuses on restoration after more significant aging has occurred. Retail prices run from $155 to $175, placing this firmly at the top end of prestige skincare.
US website availability begins April 20, 2026. Brick-and-mortar and major luxury retail partners follow May 1.
Board-Certified Dermatologists in the Room from Day One
Lancôme’s choice to debut the line at AAD, the largest annual gathering of dermatologists in North America, was deliberate. The brand assembled a Longevity MD Advisors Board comprising four board-certified physicians: David Luu, Tiffany Moon, Gabrielle Lyon, and Amy Killen. Critically, these weren’t endorsers brought in post-launch. Annie Black, Ph.D., Lancôme’s international scientific director, stated that the board engaged throughout ingredient selection, formula development, and clinical testing.
That sequence matters. It separates dermatologist co-development from the more common practice of attaching a physician’s name to a finished product. The science was vetted before the formula was built.
Cell BioPrint: Measuring What Age Really Means for Skin
Alongside the products, Lancôme introduced Cell BioPrint, a diagnostic tool that analyzes five protein biomarkers to calculate the biological age of the skin. Chronological age and biological skin age are rarely the same number, and the gap between the two is where most skincare opportunity lives. Quantifying that gap using five simultaneous protein markers is a step beyond the single-metric skin age tests that have circulated in the wellness space.
The Longevity Category Is Moving Fast
Lancôme is not launching into empty space. In 2025, Vichy, Tatcha, Sisley Paris, Clarins, and Nivea each entered the longevity skincare category with their own formulations. What sets the Absolue Longevity MD launch apart is the combination of a clinically validated ingredient, a dermatologist-led development process, and a diagnostic tool to frame the conversation in measurable terms.
The question going forward is whether consumers will treat longevity skincare as a premium upgrade to their existing routine or as a category that displaces traditional anti-aging altogether. Lancôme is betting on the latter by building the scientific credibility first and the marketing story second.